Company / Financials
Opus Genetics, Inc. Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$11.0M
FY2025 · -42.3% YoY
Net Income
-$57.5M
FY2025 · -476.1% YoY
Profit Margin
-523.4%
FY2025 · net income / revenue
ROE
-855.6%
FY2025 · return on equity
Total Assets
$50.2M
FY2025
Total Debt
$1.1M
0.17x debt/equity
Equity
$6.7M
FY2025
ROA
-114.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$11.0M-42.3% YoYNet Income HistoryProfit after all expenses and taxes-$57.5M-476.1% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$62.1M-487.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$18.2M+52.3% YoYR&D Expense HistoryResearch and development spending$26.9M+52.1% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$0-100.0% YoYEPS (Basic) HistoryBasic earnings per share-$2.15-367.4% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.15-367.4% YoYShares Outstanding HistoryWeighted average diluted shares outstanding31.6M+31.7% YoY